SAN FRANCISCO - CMEA Ventures, a venture capital firm focusing on information technology and life sciences companies, announced that Rodney D. Altman, MD will join its firm as Senior Partner. Dr. Altman will focus on medical devices, biotechnology therapeutics, and diagnostics.
Before joining CMEA Ventures, Rod was a Founder and Managing Director of Aphelion Capital, a medical device investment fund. He also worked at Piper Jaffray Ventures and TVM Techno Venture Management. Before TVM, Rod practiced emergency medicine on a full-time basis for 10 years. Dr. Altman continues to practice medicine on a limited basis at Stanford University Medical Center, where he is a Clinical Assistant Professor of Emergency Medicine in the Department of Surgery.
Tom Baruch, Founder and Managing Director of CMEA Ventures, said, “Rod is a great addition to our team. He brings with him unique and relevant experience as a physician and as an investor.”
Dr. Altman graduated from McGill University’s Faculty of Medicine as a University Scholar, and from University of Chicago’s business school with honors. He is also a Fellow of the American College of Emergency Physicians.
CMEA Ventures invests in both early and late stage companies, and actively partners with its extended network of corporations, VC firms, institutional investors, strategic partners, and entrepreneurs. CMEA Ventures manages six funds and has $771 million of capital. The firm has been an early stage investor in leading Silicon Valley companies such as Flextronics (FLEX), Maxygen (MAXY), Monogram Biosciences (MGRM - acquirer of ViroLogic), Syrrx (recently purchased by Takeda), and Symyx (SMMX). The current CMEA Ventures portfolio includes Alexza (ALZA), Alien Technology, Altus (ALTU), Ambrx, Bayhill Therapeutics, BioMimetic, Codexis, Entropic, Intermolecular, Perlegen, Predix, and XenoPort (XNPT), among others.
http://www.cmeaventures.com Media contact - Meryl Schreibstein 415.352.1520 x260
